Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning

Journal of Molecular Biology

Volumn 335, Issue 1, 2004, Pages 209-219

  Zhang, Mei Yun ^a,b   Shu, Yuuei ^a   Rudolph, Donna ^c   Prabakaran, Ponraj ^a   Labrijn, Aran F ^d   Zwick, Michael B ^d   Lal, Renu B ^c   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibody; gp140; HIV; Inhibitors; Phage display

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CROSS REACTING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY M6; MONOCLONAL ANTIBODY M9; MONOCLONAL ANTIBODY SCFV X5; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY ENGINEERING; ANTIBODY LIBRARY; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CROSS REACTION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; METHODOLOGY; MUTAGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAGING; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS TYPING;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; TRIXIS;

EID: 0344255655     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.09.055     Document Type: Article

References (29)

1. Burton D.R. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2:2002;706-713.
2. Ferrantelli F., Ruprecht R.M. Neutralizing antibodies against HIV - back in the major leagues? Curr. Opin. Immunol. 14:2002;495-502.
3. Veazey R.S., Shattock R.J., Pope M., Kirijan J.C., Jones J., Hu Q., et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature Med. 9:2003;343-346.
4. Armbruster C., Stiegler G.M., Vcelar B.A., Jager W., Michael N.L., Vetter N., et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS. 16:2002;227-233.
5. Stiegler G., Armbruster C., Vcelar B., Stoiber H., Kunert R., Michael N.L., et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS. 16:2002;2019-2025.
6. Zhang M.Y., Shu Y., Phogat S.K., Xiao X., Cham F., Choudhary A., et al. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J. Immunol. Methods. 2003;. in the press.
7. Moulard M., Zhang M.Y., Dimitrov D.S. Novel HIV neutralizing antibodies selected from phage display libraries. Subramanian G. Biopharmaceutical Antibodies. 2003;105-117 Kluwer, New York.
8. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X., Binley J.M., et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl Acad. Sci. USA. 99:2002;6913-6918.
9. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1994;1024-1027.
10. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 293:2001;1155-1159.
11. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franza T., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:2003;10557-10665.
12. Bouma P., Leavitt M., Zhang P.F., Sidorov I.A., Dimitrov D.S., Quinnan G.V. Jr. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1. J. Virol. 77:2003;8061-8071.
13. Salzwedel K., Smith E.D., Dey B., Berger E.A. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J. Virol. 74:2000;326-333.
14. Dey B., Del Castillo C.S., Berger E.A. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol. 77:2003;2859-2865.
15. Xiao X., Wu L., Stantchev T.S., Feng Y.R., Ugolini S., Chen H., et al. Constitutive cell surface association between CD4 and CCR5. Proc. Natl Acad. Sci. USA. 96:1999;7496-7501.
16. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J.L., Harvey P.E., Sharron M., et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl Acad. Sci. USA. 99:2002;16249-16254.
17. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
18. Nussbaum O., Broder C.C., Berger E.A. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 68:1994;5411-5422.
19. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann S.E., Stanfield R., Wilson I.A., et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J. Virol. 76:2002;7306-7321.
20. Daugherty P.S., Chen G., Iverson B.L., Georgiou G. Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc. Natl Acad. Sci. USA. 97:2000;2029-2034.
21. Clackson T., Hoogenboom H.R., Griffiths A.D., Winter G. Making antibody fragments using phage display libraries. Nature. 352:1991;624-628.
22. Clackson T., Hoogenboom H.R., Griffiths A.D., Winter G. Making antibody fragments using phage display libraries. Nature. 352:1991;624-628.
23. Barbas C.F., Burton D.R., Scott J.K., Silverman G.J. Phage Display: A Laboratory Manual. 2001;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
24. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 206:1995;935-944.
25. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:1997;7478-7487.
26. Xiao L., Owen S.M., Goldman I., Lal A.A., deJong J.J., Goudsmit J., et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology. 240:1998;83-92.
27. Owen S.M., Ellenberger D., Rayfield M., Wiktor S., Michel P., Grieco M.H., et al. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J. Virol. 72:1998;5425-5432.
28. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., Moore J.P. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74:2000;6893-6910.
29. Xiao L., Rudolph D.L., Owen S.M., Spira T.J., Lal R.B. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS. 12:1998;F137-F143.